Takeda Pharmaceuticals America, Inc. - Virtual Exhibit Hall - Mayo Clinic Nephrology, Hypertension and Kidney Transplantation Update for the Clinician 2022 | Mayo Clinic School of Continuous Professional Development

Takeda Pharmaceuticals America, Inc. - Exhibitor
Company Website Contact Information: Tawnie Houtchens, Regional Business Manager - GI Rare tawnie.houtchens@takeda.com 720-518-7117 Marc Konecny, Regional Business Manager - GI Rare marc.konecny@takeda.com 407-443-1240	Return to Virtual Exhibit Hall Takeda brings a deep appreciation for the global burden of digestive diseases and a personal understanding not only of the significant unmet clinical needs, but of the unmet human needs. It’s why for more than 25 years, Takeda, and our collaboration partners, have worked to improve the lives of patients through innovative therapies and dedicated patient support programs. It’s also the reason we’re focused on areas of gastroenterology associated with serious unmet needs like inflammatory bowel disease, immune-related diseases, liver, and motility disorders. Despite advances that have been made, there is still so much more to be done. In many ways, we’re just getting started. Takeda is committed to making a meaningful difference in the lives of those living with GI diseases. GATTEX is for patients ≥1 year of age with SHORT BOWEL SYNDROME (SBS) who are dependent on parenteral support (PS) IMPORTANT SAFETY INFORMATION Warnings and Precautions GATTEX has been associated with acceleration of neoplastic growth, intestinal obstruction, biliary and pancreatic disease, fluid imbalance and fluid overload, and increased absorption of concomitant oral medication. For the full Important Safety Information please visit www.gattexhcp.com Additional Information GATTEX HCP Branded Virtual One Pager

Takeda Pharmaceuticals America, Inc. - Exhibitor

Contact Information:

Tawnie Houtchens, Regional Business Manager - GI Rare
tawnie.houtchens@takeda.com
720-518-7117

Marc Konecny, Regional Business Manager - GI Rare
marc.konecny@takeda.com
407-443-1240

Takeda brings a deep appreciation for the global burden of digestive diseases and a personal understanding not only of the significant unmet clinical needs, but of the unmet human needs. It’s why for more than 25 years, Takeda, and our collaboration partners, have worked to improve the lives of patients through innovative therapies and dedicated patient support programs. It’s also the reason we’re focused on areas of gastroenterology associated with serious unmet needs like inflammatory bowel disease, immune-related diseases, liver, and motility disorders. Despite advances that have been made, there is still so much more to be done. In many ways, we’re just getting started. Takeda is committed to making a meaningful difference in the lives of those living with GI diseases.

GATTEX is for patients ≥1 year of age with SHORT BOWEL SYNDROME (SBS) who are dependent on parenteral support (PS)

IMPORTANT SAFETY INFORMATION
Warnings and Precautions
GATTEX has been associated with acceleration of neoplastic growth, intestinal obstruction, biliary and pancreatic disease, fluid imbalance and fluid overload, and increased absorption of concomitant oral medication.

For the full Important Safety Information please visit www.gattexhcp.com

Additional Information
GATTEX HCP Branded Virtual One Pager

Mayo Clinic School of Continuous Professional Development

You are here

Takeda Pharmaceuticals America, Inc. - Virtual Exhibit Hall - Mayo Clinic Nephrology, Hypertension and Kidney Transplantation Update for the Clinician 2022